Quantcast
Last updated on April 24, 2014 at 10:39 EDT

SORIN Acquires UCL Spin-off NeuroTECH

November 12, 2012

LOUVAIN-LA-NEUVE, Belgium, November 12, 2012 /PRNewswire/ –

SORIN [http://www.mscsoftware.com ], a global medical device company and a leader in
the treatment of cardiovascular, has acquired NeuroTECH [http://www.e-xstream.com ], a
spin-off of Universite catholique de Louvain (UCL).

Established in the end of nineties, NeuroTECH was co-founded by M. Troosters and three
members of UCL (Prof. C. Trullemans, Prof Cl. Veraart and Dr. J. Delbeke). During the
first years of the company, the spin-off of two laboratories (Neural Rehabilitation
Engineering and Microelectronics Laboratory) assisted in the development of a visual
prosthesis in the frame of European grants. A world premiere took place in 1998, with the
implantation of an optic nerve visual prosthesis at the Cliniques universitaires St-Luc,
Brussels.

In 2002, the company identified a new application for the treatment of refractory
epilepsy. A novel implantable vagus nerve stimulation system was developed. ADNS-300, CE
marked, is able not only to stimulate but also to record compound action potentials from
the vagus nerve, using this information to potentially personalize the therapy and provide
an improved outcome. Chronic recording of the compound action potentials of the vagus
nerve has been another world premiere for Neurotech, which it achieved in collaboration
with the University of Gent’s department of Epileptology of Prof. P. Boon. Other
prototypes were also developed by NeuroTECH to evaluate the use of neurostimulation to
treat either refractory obstructive sleep apnea, or movement disorders respectively.

Since its inception, SOPARTEC, a wholly owned subsidiary of UCL and manager of VIVES
Louvain Technology Funds was one of the co-founders and an early investor in the company.
From 2005 onwards, the company was funded by VIVES I and SRIW.

“I am very pleased that the unique technological building blocks we have developed for
our products, can now be used for the treatment of debilitating diseases otherwise
refractory to other treatments, within SORIN GROUP,” said Mr. Michel Troosters, founder
and past CEO.

“This acquisition represents a further important step forward in our long-term growth
initiatives as announced in our recent Strategic Plan,” said Andre-Michel Ballester, Chief
Executive Officer of Sorin Group.

Bruno Delvaux, Rector of UCL, added: “Building bridges between science and industry
for the benefits of society is one of the key missions of UCL. Our research, through an
integrated technology transfer process, contributes directly to address unmet therapeutic
needs.”

About NeuroTech

Founded in 1994 as a spin-off of Universite catholique de Louvain, NeuroTECH’s mission
(http://www.neurotech-int.eu) is to design, develop and bring to market cost-effective
active implantable medical devices improving the quality of life of patients suffering
from neurological, psychiatric and related disorders. Neurotech’s first commercial
product, an implantable vagus nerve stimulator, presents two key differentiators: the
ADNS-300 uses a rechargeable battery and not only stimulates the vagus nerve but also
records neural activity from the left vagus nerve using an innovative cuff electrode. This
unique sensing feature enables the physician to capture the “compound action potential”
(CAP) generated by the stimulation, which should allow an improved and personalized
treatment.

About Sorin Group

Sorin Group (Reuters Code: SORN.MI) is a global medical device company and a leader in
the treatment of cardiovascular diseases. The Company develops, manufactures, and markets
medical technologies for cardiac surgery and for the treatment of cardiac rhythm
disorders. With 3,750 employees worldwide, Sorin Group focuses on three major therapeutic
areas: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems),
cardiac rhythm management, and heart valve repair and replacement. Every year, over one
million patients are treated with Sorin Group devices in more than 80 countries.
(http://www.sorin.com )

About SOPARTEC-LTTO-VIVES

The Louvain Technology Transfer Office (LTTO) was created as a partnership between the
UCL Research Administration (ADRE) and SOPARTEC SA (http://www.sopartec.com) to
connect industry with academic science and transfer UCL’s discoveries from the lab to the
market. The technology transfer activities contribute to develop new products and solve
problems thanks to research initiated by UCL. They foster innovation in combination with
high level of research and education. At UCL, the transfer of technologies dates back to
the early nineties. More than 50 spinoff companies, which today generate more than 3,000
jobs, contribute to new economic activity and to the development of society. SOPARTEC is
also the managing company of a EUR43m VIVES Louvain Technology Fund, the largest European
investment fund ever initiated by a university. VIVES is a multi-sectorial technology
investment fund that invests in spin-offs of Universite catholique de Louvain (UCL) as
well as start-ups in Belgium and neighboring countries. The objective of the fund is to
invest in the development of start-ups, from technological validation through commercial
maturity. Please visit : http://www.llto.com http://www.vivesfund.com

About UCL

Founded in 1425, the Universite catholique de Louvain (UCL) is one of Europe’s oldest
universities. It offers hundreds of educational programmes to more than 27,000 students
from some 120 countries. UCL is ranked 125th in the QS World University Rankings
(2011-2012), making it the number one university in the French Community of Belgium.
Education, Research and Service to Society are the three fundamental missions of UCL.
Anchored in a tradition of excellence, they have always opened up UCL to its region,
Europe and the world. Research is closely linked to learning and teaching and is the
raison d’etre and the driving force of the university’s activity. Often applied but also
implied, research at UCL is the day-to-day activity of responsible and passionate men and
women. Whether in the short or long term, research constitutes one of the best investments
in economic, social and cultural terms. Financing research, like financing education and
health, must count among the highest priorities of a country and constitutes the pride of
an advanced society. Please visit : http://www.uclouvain.be

About SRIW

SRIW (Societe Regionale d’Investissement de Wallonie) provides finance within and
outside Belgium for businesses undertaking industrial projects or providing services that
generate added value in the Walloon Region of Belgium. For the last 30 years, the company
has in this way been facilitating the Walloon Region of Belgium’s economic development,
contributing effectively and in real terms to the modernisation, growth and restructuring
of the businesses that make up our industrial fabric. http://www.sriw.be

SOURCE Sopartec SA


Source: PR Newswire